Continuing Education
for Urology & GU Oncology Clinicians

Conference Coverage: ESMO 2019 Bladder

Barcelona, Spain ( Treatment options for advanced urothelial cancers (UC) are limited, and the development of more effective therapies is a clear unmet need. In this session, Dr. Loriot discussed the previous two presentations: EV-103 looking at the combination of enfortumab vedotin (EV) and pembrolizumab as first line therapy in locally advanced and metastatic UCs, and BISCAY looking at targeted therapies based on tumor genomics in combination with standard of care durvalumab in platinum-refractory UC patients.